Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain

References

• GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954–976.
   PubMed Web of Science ®Google Scholar
• International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
   Web of Science ®Google Scholar
• Matías-Guiu J, Porta-Etessam J, Mateos V, et al. Scientific committee of the PALM program one-year prevalence of migraine in Spain: a nationwide population-based survey. Cephalalgia. 2011;31:463–470.
   PubMed Web of Science ®Google Scholar
• Garrido M, Gálvez D, Brace O, et al. Grupo de Trabajo Multidisciplinar del Atlas de Migraña en España. Impacto y situación de la migraña en España: atlas 2018. Sevilla: Editorial Universidad de Sevilla; 2018. [cited 2019 Apr 1]. Available from: http://www.dolordecabeza.net/wp-content/uploads/2018/11/3302.-Libro-Atlas-Migaraña_baja.pdf
   Google Scholar
• Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81–89.
   PubMed Web of Science ®Google Scholar
• Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361–378.
   PubMed Web of Science ®Google Scholar
• Dodick DW. Migraine. Lancet. 2018;391:1315–1330.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644–655.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS ONE. 2015;10:e0130733.
   PubMed Web of Science ®Google Scholar
• Berger A, Bloudek LM, Varon SF, et al. Adherence with migraine prophylaxis in clinical practice. Pain Pract. 2012;12:541–549.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–488.
   PubMed Web of Science ®Google Scholar
• Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394:1765–1774.
   PubMed Web of Science ®Google Scholar
• Reuter U. A review of monoclonal antibody therapies and other preventative treatments in migraine. Headache. 2018 May;58(Suppl 1):48–59.
   PubMedGoogle Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6.
   PubMed Web of Science ®Google Scholar
• Ernst FR1, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41:192–199.
   PubMedGoogle Scholar
• Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm. 2001;58:1126–1132.
   PubMed Web of Science ®Google Scholar
• Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm. 2004;10:259–265.
   PubMedGoogle Scholar
• Goldberg LD. The cost of migraine and its treatment. Am J Manag Care. 2005;11(2 Suppl):S62–7.
   PubMed Web of Science ®Google Scholar
• Isla D, De Castro J, Juan O, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinic Econ Outcomes Res. 2017;9:31–38.
   PubMed Web of Science ®Google Scholar
• Anguita P, González C, Cañete M, et al. Coste de los efectos adversos asociados a enzalutamida o apalutamida en el tratamiento del cáncer de próstata resistente a la castración no metastásico en España. Rev Esp Econ Salud. 2019;14:794–805.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford (UK): Oxford University Press; 2006.
   Google Scholar
• Diener HC, Dodick DW, Turkel CC, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21:851–859.
   PubMed Web of Science ®Google Scholar
• Winner PK, Blumenfeld AM, Eross EJ, et al. Long-term safety and tolerability of onabotulinumtoxinA treatment in patients with chronic migraine: results of the COMPEL study. Drug Saf. 2019;42:1013–1024.
   PubMed Web of Science ®Google Scholar
• A long-term efficacy, safety, and tolerability study of BOTOX® in patients with chronic migraine. [ cited 2020 Jan 29]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01516892?term=COMPEL+study&draw=2&rank=1
   Google Scholar
• Comparing efficacy and safety of 2 dose regimens of subcutaneous Administration of TEV-48125 versus placebo for the preventive treatment of chronic migraine. [ cited 2019 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02621931?term=fremanezumab&rank=7
   Google Scholar
• Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. [ cited 2019 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02629861?term=fremanezumab&rank=6
   Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–2122.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal EM, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999–2008.
   PubMed Web of Science ®Google Scholar
• An efficacy and safety study of fremanezumab in adults with migraine (FOCUS). [ cited 2019 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03308968
   Google Scholar
• Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030–1040.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention (STRIVE). [ cited 2019 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02456740?term=erenumab&draw=2&rank=14
   Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–2132.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of erenumab (AMG 334) compared to placebo in migraine prevention (ARISE). [ cited 2019 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02483585?term=erenumab&rank=10
   Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37. (b).
   Web of Science ®Google Scholar
• Evaluation of galcanezumab in the prevention of episodic migraine- the EVOLVE-1 study (EVOLVE-1). [ cited 2019 Apr 15]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02614183?term=Galcanezumab&draw=2&rank=11
   Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080–1088.
   PubMed Web of Science ®Google Scholar
• Evaluation of efficacy & safety of galcanezumab in the prevention of episodic migraine- the EVOLVE-2 study (EVOLVE-2). [ cited 2019 Apr 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02614196?term=evolve+2&rank=1
   Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442–1454.
   PubMed Web of Science ®Google Scholar
• Evaluation of galcanezumab in the prevention of chronic migraine (REGAIN). [ cited 2019 Apr 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02614261?term=GALCANEZUMAB+REGAIN&rank=1
   Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211–21.
   PubMed Web of Science ®Google Scholar
• Bigal EM, Dodick DW, Krymchantowski AV, et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87:41–48.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–434.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280–2287.
   PubMed Web of Science ®Google Scholar
• Orden 727/2017, de 7 de agosto, del Consejero de Sanidad, por la que se fijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la red de centros de la Comunidad de Madrid. [Order 727/2017, dated 7 August, of the Regional Minister of Health, setting the public prices for the provision of health services and activities of the network of centres in the Community of Madrid]. Official Gazette of the Community of Madrid No. 198; 2017 Aug 21.
   Google Scholar
• Tarifas para facturación de servicios sanitarios y docentes del Servicio vasco de salud para el año 2019. [Rates for billing of health and teaching services of the Basque Health Service for 2019]. Vitoria: Basque Health Department; 2019 Feb.
   Google Scholar
• Asensio A, Bouza E, Grau S, et al. Coste de la diarrea asociada a Clostridium difficile en España. Rev Esp Salud Pública. 2013;87:37–44.
   Web of Science ®Google Scholar
• Barrientos-Ruiz I, Serrano Montilla J, Ortiz-Cruz EJ. Análisis de los costes de diagnóstico y tratamiento de los sarcomas de partes blandas en centros de referencia. Rev Esp Cir Ortop Traumatol. 2012;56:374–377.
   PubMedGoogle Scholar
• Betegón L, Canal C, Escolar G, et al. Cost-effectiveness analysis of apixaban versus dabigatran for prevention of stroke in patients with non-valvular atrial fibrillation in Spain. Eur J Clin Pharm. 2014;16:325–338.
   Google Scholar
• González Y, Sicras A, Larraínzar R, et al. Estimación de los costes sanitarios relacionados con las fracturas osteoporóticas en pacientes posmenopáusicas en España. Pharmaco Econ Span Res Art. 2015;12:1–9.
   Google Scholar
• Mapfre. Estudio de evaluación económica de la accidentabilidad de las personas mayores en España. Madrid: Fundación Mapfre; 2012 Nov.
   Google Scholar
• Oyagüez I, Frías C, Sguí MA, et al. Eficiencia de tratamientos oncológicos para tumores sólidos en España. Farm Hosp. 2013;37:240–259.
   PubMedGoogle Scholar
• Rejas Gutiérrez J, Blanca Tamayo M, Gascón Barrachina J, et al. Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain. Rev Psiquiatr Salud Ment. 2016;9:87–96.
   PubMed Web of Science ®Google Scholar
• Rubio-Terrés C, Graefenhain de Codes R, Rubio-Rodríguez D, et al. Cost-effectiveness analysis of rivaroxaban versus acenocoumarol in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain. J Health Econ Outcom Res. 2016;4:19–34.
   Google Scholar
• Sicras-Mainar A, Navarro-Artieda R. Cost of arterial hypertension according to levels of morbidity in primary care setting. Med Clin (Barc). 2009;133:290–295.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention (2018). [ cited 2019 Dec 3]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02066415?term=erenumab+chronic&draw=2&rank=1
   Google Scholar
• Haanes KA, Edvinsson L, Sams A. Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies. J Headache Pain. 2020;21:26.
   PubMed Web of Science ®Google Scholar
• Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515–526.
   PubMed Web of Science ®Google Scholar
• Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology. 2020;94:e497–e510.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Instructions and guidelines. Version 3.0, Release 4; 2008 Jan 15 cited 2020 Apr 28. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/cdus_ig_3r4.pdf
   Google Scholar